Baohuoside I (CAS: 113558-15-9) is a bioactive flavonoid glycoside isolated from Epimedium brevicornum (Horny Goat Weed), with validated purity ≥98% by HPLC. As a potent CXCR4 chemokine receptor inhibitor and apoptosis inducer, it demonstrates significant anti-tumor efficacy.
제품명 :
Baohuoside ICAS 번호 :
113558-15-9모습 :
Light yellow to yellow crystalline powder사양 :
98%Plant Source: Epimedium brevicornum Maxim. (Barrenwort)
Molecular Formula: C₂₇H₃₀O₁₀
Molecular Weight: 514.5 g/mol
Purity: ≥98% (HPLC-validated)
Appearance: Light yellow to yellow crystalline powder
Chemical & Physical Properties
Property |
Value |
Melting Point |
202–203 °C |
Boiling Point |
759.4±60.0 °C (760 mmHg) |
Density |
1.46–1.5±0.1 g/cm³ |
Solubility |
Soluble in DMSO, methanol; insoluble in water |
Optical Activity |
[α]/D -101° to -129° (c=0.5, ethanol) |
Storage |
2–8°C, sealed, dry, protected from light |
Product Specifications
CAS No.: 113558-15-9
Synonyms: Icariside II, Anhydroicaritin, Baohuoside I
Purity: ≥98% (HPLC, UV detection at 270 nm)
Packaging: 20 mg, 100 mg, 500 mg, 1 g,10g,100g,1kg (custom bulk available)
Stability: Stable for 2 years under recommended storage; avoid freeze-thaw cycles in solution
Biological Activities & Mechanisms
In Vitro & In Vivo Efficacy
Anti-Cancer Activity:
Inhibits CXCR4 chemokine receptor (IC₅₀: 12–25 μM), suppressing invasion of cervical and breast cancer cells.
Induces apoptosis in non-small cell lung cancer (A549) via ROS-mediated JNK/p38 MAPK activation and caspase cascade inhibition (IC₅₀: 9.6–25.1 μM) .
Blocks esophageal squamous carcinoma (Eca109) growth (IC₅₀: 4.8 μg/mL at 48 h) by downregulating β-catenin, cyclin D, and survivin.
Anti-Metastatic Effects:
Suppresses CXCL12-induced cancer cell invasion by dose-dependent inhibition of NF-κB signaling.
Osteoprotective Action:
Mitigates glucocorticoid-induced osteoporosis in zebrafish models by enhancing osteoblast activity.
Clinical & Research Applications
Oncology: Therapeutic candidate for lung, breast, cervical, and esophageal cancers via CXCR4/NF-κB targeting.
Bone Health: Potential agent against osteoporosis by promoting bone formation.
Synergistic Therapy: Enhances efficacy of 5-FU in apoptosis induction by modulating Bcl-2/Bax expression.
Experimental Protocols
Cell-Based Assays:
Use in DMSO at 10–25 μM working concentrations (MTT assay for viability).
Centrifuge vials before reconstitution to prevent compound adhesion .
Animal Studies:
Tumor xenograft models: 25 mg/kg intralesional injection in nude mice, significant suppression of cyclin D1/survivin.
Ordering & Support
Quality Assurance: Batch-specific HPLC, MS, NMR reports provided.
Customization: Bulk quantities (up to kg-scale), extraction from Epimedium spp. upon request.
Shipping: Ambient temperature (powder); dry ice for solutions.